Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma
Status:
Completed
Trial end date:
2018-04-11
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of ipilimumab when given together
with whole brain radiation therapy or stereotactic radiosurgery in treating patients with
melanoma with brain metastases. Monoclonal antibodies, such as ipilimumab, can block tumor
growth in different ways. Some block the ability of the tumor to grow and spread. Others find
Tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy,
such uses high-energy x-rays and other types of radiation to kill tumor cells. Giving
radiation therapy in different ways may kill more tumor cells. Giving ipilimumab together
with whole-brain radiation therapy or stereotactic radiosurgery may kill more tumor cells.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University